MT-act is a CNRS spin-off and is developing a new first-in-class drug candidate that targets microtubule (MT) function. Microtubules are the constituent fibers of the cytoskeleton and constitute the molecular framework for maintaining the three-dimensional shape of cells. There are many pathologies linked to biochemical abnormalities of microtubules and this is what we act on.
MT-act
Address :
CNRS Balard Building CIT 1919 Route de Mende34293 Montpellier Cedex 5